Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9GZX6
UPID:
IL22_HUMAN
Alternative names:
Cytokine Zcyto18; IL-10-related T-cell-derived-inducible factor
Alternative UPACC:
Q9GZX6
Background:
Interleukin-22 (IL-22), also known as Cytokine Zcyto18 or IL-10-related T-cell-derived-inducible factor, plays a pivotal role in modulating tissue responses during inflammation. It is essential for the regeneration of epithelial cells to maintain barrier function after injury, preventing further tissue damage. IL-22 signals through a heterodimeric receptor composed of IL22RA1 and IL10RB subunits, activating pathways such as JAK1/TYK2 and STAT3, which promote cell survival and proliferation.
Therapeutic significance:
Understanding the role of Interleukin-22 could open doors to potential therapeutic strategies, especially in conditions where tissue regeneration and inflammation modulation are crucial.